Modern Diagnostic & Research Centre submits voting results of 14th AGM

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights
  • Modern Diagnostic & Research Centre submitted voting results for its 14th AGM held on September 30, 2026
  • All three ordinary resolutions passed with 100% votes in favour and zero against
  • Total valid votes cast stood at 11,379,178, representing 75.36% of outstanding shares
  • Resolutions covered FY26 financial statements adoption, director re-appointment, and auditor re-appointment
powered bylight_fuzz_icon
52327476

*this image is generated using AI for illustrative purposes only.

Modern Diagnostic & Research Centre Limited has submitted the voting results of its 14th Annual General Meeting (AGM) held on September 30, 2026. The company filed the scrutinizer's report and voting outcomes with BSE Limited pursuant to SEBI listing regulations.

The meeting, conducted at Jaypee Siddharth 3 in New Delhi, saw the unanimous approval of all three ordinary resolutions proposed by the board. These included the adoption of audited financial statements for FY26, the re-appointment of a director, and the re-appointment of the statutory auditor.

Voting participation and attendance

A total of 408 shareholders were on the record date as of September 23, 2026. Of these, 18 shareholders attended the meeting either in person or through proxy. This comprised 5 members from the promoter and promoter group and 13 public shareholders. No shareholders attended via video conferencing or other audio-visual means.

Voting was conducted through remote e-voting between September 27 and September 29, 2026, supplemented by ballot papers at the meeting venue. The e-voting facility was provided by MUFG Intime India Private Limited.

Resolution outcomes

All three resolutions passed with 100% of the votes polled in favor and zero votes against. The total number of valid votes cast across all categories was 11,379,178, representing 75.36% of the total outstanding shares.

Resolution Description Votes in Favour Votes Against Result
1 Adoption of Audited Financial Statements for FY26 11,379,178 0 Passed
2 Re-appointment of Deepali Yadav as Director 11,379,178 0 Passed
3 Re-appointment of Gupta Aiyer & Co. as Statutory Auditor 11,379,178 0 Passed

Governance and board composition

Mr. Devendra Singh Yadav, Managing Director, presided over the meeting. The board composition included two executive directors, one non-executive director, and two independent directors. Key Managerial Personnel present included Mr. Jitendra Singh, Chief Financial Officer, and Mrs. Priyanshu Yadav, Company Secretary & Compliance Officer.

Name Designation
Devendra Singh Yadav Managing Director
Deepali Yadav Whole-time Director
Ajay Kohli Non-executive Director
Sanjay Khandelwal Independent Director
Rishabh Kumar Jain Independent Director

Scrutinizer's report details

Mr. Kuldeep Singh Bisht, Practicing Company Secretary from Kuldeep Bisht & Associates, served as the scrutinizer. His report confirmed that the voting process was fair and transparent. The votes were unblocked in the presence of two witnesses who were not employees of the company.

The statutory auditor re-appointed is M/s. Gupta Aiyer & Co., Chartered Accountants, for a period of five years. Mrs. Deepali Yadav (DIN: 06496670) was re-appointed as a director liable to retire by rotation.

Historical Stock Returns for Modern Diagnostic & Research Centre

1 Day5 Days1 Month6 Months1 Year5 Years
-2.16%-3.18%-24.55%0.0%-34.08%-34.08%

How will the adoption of the FY26 audited financial statements influence Modern Diagnostic's future capital allocation and dividend payout strategy?

What specific growth initiatives or operational expansions are planned under Deepali Yadav's new tenure as Whole-time Director?

Given the 75.36% voting turnout, how might the company address the remaining 24.64% of shareholders to enhance future governance participation?

Modern Diagnostic & Research Centre
View Company Insights
View All News
like20
dislike

Modern Diagnostic revenue up 7% in FY26; PAT falls 42% to ₹52.5 crore

scanx
Reviewed by
Naman SScanX News Team
Key Highlights
  • Operating income rose 6.6% YoY to ₹8,311.06 lakh in FY26
  • Profit after tax fell 41.7% to ₹525.33 lakh amid higher expenses
  • EBITDA margin contracted to 16.18% from 24.00% in FY25
  • 14th AGM scheduled for September 30, 2026, to approve financials
  • Company launched five new labs and expanded specialized diagnostics
powered bylight_fuzz_icon
49984996

*this image is generated using AI for illustrative purposes only.

Modern Diagnostic & Research Centre reported a 6.8% rise in operating income to ₹8,311.06 lakh for FY26, while profit after tax (PAT) declined 41.7% to ₹525.33 lakh. The company has scheduled its 14th Annual General Meeting (AGM) for September 30, 2026, to adopt these audited financial statements.

The Board of Directors approved the AGM notice on September 3, 2026. The meeting will be held at Jaypee Siddharth 3 in New Delhi. Key agenda items include the re-appointment of director Smt. Deepali Yadav and statutory auditor M/s. Gupta Aiyer & Co. The board also considered governance matters under Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance Highlights

Modern Diagnostic’s total income stood at ₹8,413.71 lakh, up from ₹7,880.46 lakh in FY25. Total expenses increased to ₹7,814.58 lakh from ₹6,593.49 lakh in the previous year. EBITDA margin contracted to 16.18% from 24.00% in FY25.

Metric FY26 FY25 Change
Operating Income ₹8,311.06 lakh ₹7,794.54 lakh +6.6%
Total Income ₹8,413.71 lakh ₹7,880.46 lakh +6.8%
Profit Before Tax ₹599.13 lakh ₹1,286.97 lakh -53.4%
Profit After Tax ₹525.33 lakh ₹900.79 lakh -41.7%
EBITDA Margin 16.18% 24.00% -782 bps

Book Closure and E-Voting Details

Pursuant to Regulation 42 of the Listing Regulations, the register of members and share transfer books will remain closed from September 23, 2026, to September 30, 2026. The record date for determining voting eligibility is September 23, 2026.

Shareholders can exercise their right to vote electronically via MUFG Intime India Private Limited. The e-voting period begins on September 27, 2026, at 9:00 am and ends on September 29, 2026, at 5:00 pm.

Corporate Governance Approvals

The board took note of the certificate of compliance of Integrated Corporate Governance for the quarter ended June 30, 2026. It approved the Director Responsibility Statement and the Secretarial Audit Report for the financial year ended March 31, 2026.

Director and Auditor Re-appointments

Smt. Deepali Yadav (DIN-06496670), who retires by rotation, was re-appointed as a director. The board also approved the re-appointment of CA Shammi Bansal, a partner at Gupta Aiyer & Co., as the Statutory Auditor for a term of five years until the conclusion of the AGM in 2031.

Operational Updates and Expansion

The board approved the Annual Report on CSR activities for FY26 and sanctioned the budget for CSR expenditures for FY27. In an operational update, the board terminated a business agreement with an associate managing the laboratory at Jaipur.

The company expanded its network by launching five new laboratories in Gurugram, East Delhi, Meerut, and Mohali. Infrastructure work for centres in Aligarh and Lucknow is nearly complete. Modern Diagnostic also introduced specialized diagnostic offerings, including LC-MS/MS-based Therapeutic Drug Monitoring panels.

Scrutinizer Profile

M/s. Kuldeep Bisht & Associates has been appointed as the scrutinizer for the 14th AGM. The firm will monitor the e-voting process to ensure regulatory compliance and transparency. Mr. Kuldeep Singh Bisht, an Associate Member of the Institute of Company Secretaries of India, brings over six years of experience in corporate secretarial matters.

Historical Stock Returns for Modern Diagnostic & Research Centre

1 Day5 Days1 Month6 Months1 Year5 Years
-2.16%-3.18%-24.55%0.0%-34.08%-34.08%

How will the termination of the Jaipur laboratory agreement impact Modern Diagnostic's regional market share and revenue growth in North India?

What specific cost-control measures is management implementing to reverse the 782 bps contraction in EBITDA margins observed in FY26?

Will the launch of specialized LC-MS/MS Therapeutic Drug Monitoring panels significantly differentiate Modern Diagnostic from competitors and improve long-term profitability?

Modern Diagnostic & Research Centre
View Company Insights
View All News
like19
dislike

More News on Modern Diagnostic & Research Centre

1 Year Returns:-34.08%